Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Sibutramine

Stage Phase 3Stale

Sponsor Abbott

Route oral

Class Monoamine reuptake

Mechanism serotonin and noradrenaline reuptake inhibitor

Sources

registry, as of 2010-05-11Stale

https://clinicaltrials.gov/study/NCT00234832

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients. Overall status COMPLETED. Phases PHASE3. Lead sponsor Abbott. Enrollment 10777. Conditions Obesity. The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event. diarrhea Lead-in Period Sibutramine 0 nausea Lead-in Period Sibutramine 0 vomiting Lead-in Period Sibutramine 0 diarrhea Randomized Sibutramine 4 nausea Randomized Sibutramine 2 vomiting Randomized Sibutramine 1 diarrhea Randomized Placebo 7 nausea Randomized Placebo 5 vomiting Randomized Placebo 5

ClinicalTrials.gov NCT00234832 protocol and results modules

registry, as of 2007-08-31Stale

https://clinicaltrials.gov/study/NCT00261911

A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.. Overall status COMPLETED. Phases PHASE3. Lead sponsor Abbott. Enrollment 498. Conditions Obesity. The purpose of this study is to assess the effectiveness of sibutramine on weight loss, reduction in body size and improvement in metabolic risk factors and safety in obese adolescents.

ClinicalTrials.gov NCT00261911 protocol and results modules

registry, as of 2008-03-27Stale

https://clinicaltrials.gov/study/NCT00645255

Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects. Overall status TERMINATED. Phases PHASE3. Lead sponsor Abbott. Enrollment 466. Conditions Obesity; Weight Loss. The study was designed to evaluate the long term efficacy and safety of Meridia 15 mg daily in obese subjects.

ClinicalTrials.gov NCT00645255 protocol and results modules

registry, as of 2007-08-31Stale

https://clinicaltrials.gov/study/NCT00402584

A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder. Overall status COMPLETED. Phases PHASE3. Lead sponsor Abbott. Enrollment 304. Conditions Binge Eating Disorder; Obesity. The purpose of this study is to examine the safety and efficacy of sibutramine in preventing binge eating episodes. Additionally the study aim is to evaluate the safety and efficacy of sibutramine in reducing body weight in subjects with binge-eating disorder.

ClinicalTrials.gov NCT00402584 protocol and results modules

registry, as of 2009-08-12Stale

https://clinicaltrials.gov/study/NCT00134199

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects. Overall status COMPLETED. Phases PHASE2,PHASE3. Lead sponsor Pfizer. Enrollment 282. Conditions Obesity. To evaluate the effect of 6-month administration of CP-945,598 on: * weight loss and waist circumference, * blood pressure, cholesterol, glucose * other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α and hsCRP * the relationship between the conce

ClinicalTrials.gov NCT00134199 protocol and results modules

registry, as of 2008-05-19Stale

https://clinicaltrials.gov/study/NCT00679653

Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives. Overall status COMPLETED. Phases PHASE3. Lead sponsor Abbott. Enrollment 171. Conditions Obesity; Hypertension. To study the effect of sibutramine treatment on weight reduction and blood pressure improvement in three groups with antihypertensive therapy whose blood pressure was not adequately controlled with antihypertensive combination treatment.

ClinicalTrials.gov NCT00679653 protocol and results modules

registry, as of 2008-05-14Stale

https://clinicaltrials.gov/study/NCT00677391

Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population. Overall status COMPLETED. Phases PHASE3. Lead sponsor Abbott. Enrollment 103. Conditions Obesity. The primary objective of this study was to evaluate the efficacy and the safety of sibutramine vs. placebo in combination with a hypocaloric diet on weight-loss in overweight and obese Malaysian subjects.

ClinicalTrials.gov NCT00677391 protocol and results modules

registry, as of 2009-07-17Stale

https://clinicaltrials.gov/study/NCT00941382

Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Laboratorios Silanes S.A. de C.V.. Enrollment 60. Conditions Obesity. The aim of this study is to evaluate the effect of sibutramine and metformin combination therapy in comparison with sibutramine or metformin monotherapy over weight, adiposity, glucose metabolism and inflammatory state in obese patients.

ClinicalTrials.gov NCT00941382 protocol and results modules

publication, as of 2004-05-21Stale

https://pubmed.ncbi.nlm.nih.gov/15013931/

Sibutramine and the management of obesity. Sibutramine is a selective serotonin and noradrenaline re-uptake inhibitor approved for the long-term management of obesity. Its primary mechanism of action is increased satiety, although some evidence also suggests increased energy expenditure could pla

PMID 15013931

Studies

SCOUT

Registry NCT00234832

Phase Phase 3

Status Completed

Enrollment 10777

Sibutramine

Regimen once daily

Comparator placebo

Population Obesity

participants with diarrhea, 0 participantsStale

participants with nausea, 0 participantsStale

participants with vomiting, 0 participantsStale

Placebo

Regimen once daily

Population Obesity

participants with diarrhea, 7 participantsStale

participants with nausea, 5 participantsStale

participants with vomiting, 5 participantsStale

Lead-in sibutramine

Regimen once daily

Comparator placebo

Population Obesity

A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.

Registry NCT00261911

Phase Phase 3

Status Completed

Enrollment 498

Registry arm not named

Population Obesity

Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochloride in Obese Subjects

Registry NCT00645255

Phase Phase 3

Status Terminated

Enrollment 466

1

Regimen weekly

Comparator placebo

Population Obesity; Weight Loss

2

Regimen weekly

Population Obesity; Weight Loss

A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder

Registry NCT00402584

Phase Phase 3

Status Completed

Enrollment 304

Registry arm not named

Population Binge Eating Disorder; Obesity

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

Registry NCT00134199

Phase Phase 2/3

Status Completed

Enrollment 282

Registry arm not named

Population Obesity

HOS

Registry NCT00679653

Phase Phase 3

Status Completed

Enrollment 171

1

Regimen once daily

Population Obesity; Hypertension

2

Regimen once daily

Population Obesity; Hypertension

3

Regimen once daily

Population Obesity; Hypertension

Efficacy and Safety Study of Sibutramine in Overweight Non-Diabetic Malaysian Population

Registry NCT00677391

Phase Phase 3

Status Completed

Enrollment 103

1

Regimen once daily

Comparator placebo

Population Obesity

2

Regimen once daily

Population Obesity

Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients

Registry NCT00941382

Phase Phase 3

Enrollment 60

Sibutramin-Metformin

Population Obesity

Sibutramine

Population Obesity

Metformin

Population Obesity